arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Aptevo Therapeutics Inc.

APVO

$4.19 ▲ +0.19 (+4.75%) at close

12 Visible periods

29 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Aptevo Therapeutics Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.3M

Dividend Yield —

Revenue Growth None

Op. Margin None

ROIC -151.4% ↗

FCF / Share $-81.11

Trailing P/E —

Price / Book 0.2x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

12-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$3.11M

↓ -74.7% —

Net Income Profit after all expenses

$-25.97M

↓ -7.6% —

Operating Margin Operating profit as % of sales

-174.1%

↓ -32.5% —

Long-Term Debt Long-term obligations

$0.00

↓ -100.0% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Revenue Growth YoY (%)	—	—	—	-74.7% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1033%)	185.3% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+2216%)	-86.7% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1184%)	40.6% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+407%)	57.4% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+617%)	46.8% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+485%)	-70.3% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-979%)	—	—
EPS Growth YoY (%)	99.7% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	94.6% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	N/M	N/M	—	—	—	—	—	—	—	—
Net Income Growth YoY (%)	-7.6% Weak Weak Year-over-year change in net income	-38.6% Weak Weak Year-over-year change in net income	N/M	N/M	-60.3% Weak ↓ Weak Declining Year-over-year change in net income	56.1% Excellent Excellent Year-over-year change in net income	24.7% Good Good Year-over-year change in net income	N/M	N/M	-89.5% Weak Weak Year-over-year change in net income	—	—
Revenue CAGR 3Y (%)	—	—	—	-54.2% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	-18.9% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	-33.5% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	48.1% Excellent Excellent Compound annual revenue growth over 3 years	-11.8% Weak Weak Compound annual revenue growth over 3 years	—	—	—	—
Revenue CAGR 5Y (%)	—	—	—	-26.6% Weak ↓ Weak Declining Compound annual revenue growth over 5 years	4.2% Fair Fair Compound annual revenue growth over 5 years	-33.7% Weak Weak Compound annual revenue growth over 5 years	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Operating Margin (%) (%)	—	—	—	—	-174.1% Weak → Weak Stable Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1261%)	—	-131.4% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-976%)	-224.0% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1593%)	-368.1% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2554%)	—	-181.8% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1312%)	—
Effective Tax Rate (%) (%)	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—	—	—	—	41.7% Weak ↑ Weak Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	14.1% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	3.3% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
Profit Margin (%) (%)	—	—	—	—	-231.5% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2029%)	-411.9% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3533%)	-124.7% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1140%)	-232.8% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2040%)	47.6% Excellent Excellent Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+296%)	—	-176.5% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1571%)	—
FCF Margin (%) (%)	—	—	—	—	-182.2% Weak → Weak Stable Free cash flow as a percentage of revenue Optimal: > 10%	—	-131.2% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	-227.2% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-293.2% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—
FCF / Net Income (x)	0.99x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.99x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.67x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	-2.62x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.79x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.66x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	1.05x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.98x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	-6.16x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Return on Invested Capital (%)	-151.4% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-408.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-186.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-102.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-343.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-48.5% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-284.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-82.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-32.2% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-172.9% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-66.7% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-96.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-157.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-116.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-83.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-37.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-51.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-79.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-76.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-46.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-151.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	-47.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-149.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1096%)	—	-142.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1050%)	44.7% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+198%)	—	-107.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-813%)	—	-176.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1277%)	8.5% Caution ↑ Caution Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-43%)	-222.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1582%)	-66.9% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-546%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Debt to Equity (x)	—	—	0.00x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	0.22x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-63%)	3.05x Weak ↑ Weak Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+408%)	1.70x Weak ↑ Weak Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+183%)	—	0.63x Fair ↑ Fair Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+6%)	0.19x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-68%)	0.36x Good Good Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-39%)	—	—
Interest Coverage (x)	—	—	—	—	—	—	—	-26.77x Weak Weak Operating income divided by interest expense Optimal: > 5x	-30.34x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—
Net Debt (USD)	$-21.62M	$-8.71M	$-16.90M	$-18.63M	$-41.34M	$-11.76M	$-12.45M	$-11.36M	$8.63M	$8.71M	$-4.64M	$-3.59M
Debt / EBITDA (x)	—	—	0.00x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.14x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.18x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-1.08x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	-0.39x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.31x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.14x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Basic EPS, GAAP (USD)	$-87.27	$-31.46K	$-584.36K	$32.30M	$-124.90M	—	—	—	—	—	—	—
Free Cash Flow per Share (USD)	$-81.11	—	—	—	—	—	—	—	—	—	—	—
Book Value per Share (USD)	$17.42	—	—	—	—	—	—	—	—	—	—	—
Tangible Book Value per Share (USD)	$17.42	—	—	—	—	—	—	—	—	—	—	—
Basic Weighted Avg Shares (shares)	315,535	767	30	0	0	—	—	—	—	—	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Working Capital (USD)	$17.03M	$4.45M	$11.84M	$18.74M	$17.81M	$32.73M	$-8.24M	$31.08M	$76.57M	$51.87M	$15.19M	—
LT Debt (USD)	—	—	$0.00	$4.01M	$3.71M	$28.22M	—	$19.28M	$15.73M	$18.38M	—	—
Total Equity (USD)	$17.38M	$4.75M	$12.22M	$17.97M	$1.22M	$16.59M	$11.84M	$30.41M	$82.03M	$50.57M	$88.62M	$94.61M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Sales/Revenue/Turnover (USD)	—	—	—	$3.11M	$12.29M	$4.31M	$32.42M	$23.07M	$14.66M	$9.98M	$33.60M	—
Depreciation Expense (USD)	$240.00K	$352.00K	$567.00K	$901.00K	$1.14M	$1.41M	$2.23M	$2.39M	$3.13M	$3.36M	$2.91M	—
Net Income, GAAP (USD)	$-25.97M	$-24.13M	$-17.41M	$8.03M	$-28.46M	$-17.75M	$-40.45M	$-53.69M	$6.97M	$-112.42M	$-59.32M	—
Operating Cash Flow (USD)	$-25.59M	$-23.79M	$-11.73M	$-21.02M	$-21.68M	$-29.32M	$-42.38M	$-51.42M	$-41.57M	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 12 years · 44 quarters

Aptevo Therapeutics Inc.

Analytical Summary

12-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare APVO with peers